5'-DMT-dG(iBu)-Suc-CPG; 1400 Å

Catalog number: BRL-037

5'-DMT-dG(iBu)-Suc-CPG is used to add unmodified dG to the 3' end of oligonucleotides.

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Appearance

White powder

Storage

+2 to +8 °C.

Shipping

Room temperature.

Cleavage Conditions

Use concentrated ammonia for 30 minutes at 65°C when using standard amidites.

Deprotection Conditions

When using standard amidites (eg. C-Bz; G-iBu) use concentrated ammonia for 5 hours at 65°C.

Chemical Structure:

Reference Reading

2. Ibuprofen and COVID-19 disease: separating the myths from facts

Frideriki Poutoglidou, Athanasios Saitis, Dimitrios Kouvelas. Expert Rev Respir Med. 2021 Aug;15(8):979-983. doi: 10.1080/17476348.2021.1951239.

The Coronavirus disease 2019 (COVID-19) poses novel challenges in the healthcare systems around the world. Concern about the role of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and, in particular, ibuprofen has led to significant speculation.Areas covered: A literature search was conducted to evaluate ibuprofen's potential benefits and harms in the COVID-19 disease. Angiotensin-Converting Enzyme 2 (ACE-2) is crucial entry receptor for Severe Acute Respiratory Syndrome coronavirus-2 (SARS-CoV-2) in host cells. We found no scientific evidence linking ibuprofen use and an ACE-2 overexpression. Ibuprofen suppresses the production of various pro-inflammatory cytokines that are implicated in the 'cytokine storm' and subsequent ARDS in COVID-19 disease. Nevertheless, the exact role of ibuprofen in the immune response in COVID-19 disease is still unknown. There are no double-blind, placebo-controlled studies assessing the effect of ibuprofen on COVID-19 disease progression.Expert opinion: The studies that have been performed so far demonstrate no association between ibuprofen use and increased mortality rates or an increased risk for respiratory support. Accordingly, we recommend ibuprofen to be used for managing COVID-19 symptoms.

3. Ibuprofen

T G Kantor. Ann Intern Med. 1979 Dec;91(6):877-82. doi: 10.7326/0003-4819-91-6-877.

Ibuprofen was introduced in England in 1967 and in the United States in 1974 as an anti-inflammatory drug in humans. It has weak but definite anti-inflammatory properties similar to those of aspirin, milligram for milligram, but with considerably less adverse effect on the stomach. Ibuprofen is chemically related to fenoprofen and naproxen, but lack of effect for any one in this chemical class of propionic-acid derivatives does not necessarily mean lack of effect for any other in an individual patient. The drug has analgesic properties, probably related to its anti-inflammatory effect. It inhibits prostaglandin synthesis and has no effect on the adrenopituitary axis, making it a nonsteroidal agent. Ibuprofen has been shown to be effective in rheumatoid arthritis and osteoarthritis and is probably effective in ankylosing spondylitis, gout, and Bartter's syndrome.